H.C. Wainwright lowered the firm’s price target on Neurogene (NGNE) to $45 from $50 and keeps a Buy rating on the shares following the Q1 report. The firm expects positive updated clinical data in the second half of 2025, “with a clear path forward for NGN-401.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NGNE:
- Neurogene’s Promising Outlook: Strategic Focus on Safety and Efficacy Justifies Buy Rating
- Positive Outlook for Neurogene: Strategic Clinical Advancements and Strong Financial Position Drive Buy Rating
- Neurogene’s Promising Pipeline and Robust Financials Support Buy Rating Amid Regulatory Considerations
- Neurogene Reports Q1 2025 Financial Results and Advances Rett Syndrome Gene Therapy
- Promising Outlook for Neurogene: Strategic Advancements and Regulatory Prospects Justify Buy Rating